GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Institutional Ownership

Biomics Biopharma (ASX:BBM) Institutional Ownership : 0.00% (As of Jun. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biomics Biopharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biomics Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biomics Biopharma's Float Percentage Of Total Shares Outstanding is N/A.


Biomics Biopharma Institutional Ownership Historical Data

The historical data trend for Biomics Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Institutional Ownership Chart

Biomics Biopharma Annual Data
Trend
Institutional Ownership

Biomics Biopharma Semi-Annual Data
Institutional Ownership

Biomics Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biomics Biopharma (ASX:BBM) Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines